Attached files
| file | filename |
|---|---|
| EX-4.1 - FORM OF WARRANT - SCIENTIFIC INDUSTRIES INC | finalwarrantform.htm |
| EX-4.2 - REGISTRATION RIGHTS AGREEMENT BY AND AMONG THE COMPANY AND THE INVESTORS - SCIENTIFIC INDUSTRIES INC | finalregrightsform.htm |
| EX-10.3 - PURCHASE AGREEMENT BY AND AMONG THE COMPANY AND THE INVESTORS - SCIENTIFIC INDUSTRIES INC | finalspaform.htm |
| EX-99 - ADDITIONAL EXHIBITS - SCIENTIFIC INDUSTRIES INC | scnd_newboardmemberpressr.htm |
| EX-10.2 - FORM OF SERVICE AGREEMENT - SCIENTIFIC INDUSTRIES INC | directorserviceagreement.htm |
| EX-10.1 - ACQUISITION AGREEMENT BY AND AMONG THE COMPANY AND THE SELLERS - SCIENTIFIC INDUSTRIES INC | spafinal.htm |
| 8-K - 8-K - SCIENTIFIC INDUSTRIES INC | a8kaquila-1.htm |
Scientific Industries Announces Acquisition of aquila biolabs to
Advance Platform for Digitally Simplified
Bioprocessing
●
Combined companies have a target market of approximately $1.2
billion annually.
●
Transforms any bench- or production-scale culture vessel into an
intelligent device via online and real-time monitoring of process
parameters to improve time-to-market.
●
Digital technology enables bioprocessing productivity
gains.
BOHEMIA, NY and PITTSBURGH, PA /April 30, 2021
/ Scientific Industries,
Inc. (OTCQB: SCND), a life sciences tool
provider, and a developer of optical sensors for non-invasive,
real-time monitoring of cell culture systems through its subsidiary
Scientific Bioprocessing, Inc. (“SBI”), today announced
its acquisition of aquila biolabs
GmbH, a privately held German
technology developer of smart sensors and state-of-the-art
data analytics software for bioprocessing applications under agreed
upon terms. The Company believes the
acquisition positions the Company to become a leading player in the
bioprocessing industry.
John Moore, SBI’s President and Chairman of Scientific
Industries, said, “The combined technologies from
these two companies will allow us to create a new digital platform
that brings dramatic innovation and significantly enhance accuracy
in and throughput to the biopharmaceutical workflow. We now have a
target cell culture and biomanufacturing market that approximates
$1.2 billion annually that has almost no digital technology to
increase productivity. The ability to precisely tune multiple
culture parameters is essential for efficient, consistent
production of high-quality therapeutics. We believe we are well
positioned to capture market share in the coming years and are
excited about the opportunities ahead.”
The synergy of technologies developed by SBI and aquila biolabs for
real-time, non-invasive cell monitoring positions the combined
organization to advance a digital, sensor-based platform to
optimize, simplify and accelerate bioprocessing
workflows.
Once developed, the platform will enable online, real-time
monitoring of bioprocessing parameters delivering insights and
actionable data needed to develop and maintain precisely defined
and tightly controlled workflows that will improve time-to-market
and digitally simplify bioprocessing. The platform will be
compatible with a broad variety of bench- and production-scale
vessels, transforming them into data factories that can fuel
state-of-the-art machine learning and AI tools.
“As SBI explored the breadth of available technologies that
could spearhead digitally simplified
bioprocessing, aquila’s
approach stood out as the most impressive one,”
said Reinhard Vogt, Chairman of SBI and former Executive
Vice President and Member of the Board of Sartorius AG. “In
addition to a strong pipeline of advanced sensors and data
analytics tools, this strategic acquisition adds new talent to our
already strong team and expands SBI’s footprint into
Europe.”
In connection with the acquisition, aquila biolabs has entered into
new contracts with its four founders and with Daniela
Winzker-Demes, industry veteran and former Vice President of Sales
EMEA at Sartorius Lab Instruments, as SBI’s Vice President of
Sales EMEA and Asia.
“We are excited to join SBI and expand the reach of our
unique platform to bioprocess scientists around the
world,” said Daniel Grünes, co-founder of aquila
biolabs who will assume the role of vice president of R&D and
Operations at SBI. “While customers
already have access to some process parameters, there are still too
many black boxes and unknowns in bioprocessing. Our platform
combined with SBI will deliver actionable insights to our customers
to help them make the right decisions.”
“The
successful acquisition of aquila biolabs is one more step in our
Company’s path to becoming a world class life sciences tool
provider and an international company,” said Helena Santos,
CEO of Scientific Industries.
KeyBanc
Capital Markets acted as financial advisor to the Company in the
acquisition of aquila biolabs. The Company financed the acquisition
of aquila biolabs through an equity private placement. KeyBanc
Capital Markets acted as sole placement agent on the
transaction.
About Scientific Bioprocessing, Inc.
SBI is dedicated to providing state-of-the-art instruments,
strategies, and technologies to expedite the production of viable
cells and therapies with a streamlined process and product
consistency. SBI’s mission is to develop sensor technologies
and instruments that make cell culture and bioprocessing work
easier, experiments more reproducible, and culture conditions
better suited to meet experimental objectives. SBI is a subsidiary
of Scientific
Industries, Inc. To learn more, visit
www.scientificbio.com.
About Scientific Industries, Inc.
Scientific Industries (OTCQB:SCND), is a life science tool
provider. It designs, manufactures, and markets laboratory
equipment, including the world-renowned
Vortex-Genie®
2 Mixer and
Torbal®
balances,
and bioprocessing systems and methods. Scientific Industries’
products are generally used and designed for research purposes in
laboratories of universities, hospitals, pharmaceutical companies,
medical device manufacturers, and pharmacies. To learn more,
visit www.scientificindustries.com.
Safe Harbor Statement
Statements
made in this press release that relate to future events,
performance or financial results of the Company are forward-looking
statements which involve uncertainties that could cause actual
events, performance or results to materially differ. The Company
undertakes no obligation to update any of these statements. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as to the date hereof. Accordingly,
any forward-looking statement should be read in conjunction with
the additional information about risks and uncertainties set forth
in the Company's Securities and Exchange Commission reports,
including our annual report on Form 10-K.
Contact:
Sandy Williams
Marketing and Product Manager
Scientific Bioprocessing, Inc.
412-230-8463
media@scientificbio.com
www.scientificbio.com
Investor Contact:
Joe Dorame
Lytham Partners, LLC
Phone: (602) 889-9700
SCND@lythampartners.com
###